Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer

<p>Figure S7 page2</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Craig M. Goodwin (14955973) (author)
Rannpháirtithe:	Andrew M. Waters (14953065) (author), Jennifer E. Klomp (14961282) (author), Sehrish Javaid (14961285) (author), Kirsten L. Bryant (14955976) (author), Clint A. Stalnecker (14955952) (author), Kristina Drizyte-Miller (14961288) (author), Bjoern Papke (14961291) (author), Runying Yang (14961294) (author), Amber M. Amparo (14961297) (author), Irem Ozkan-Dagliyan (14961300) (author), Elisa Baldelli (14961303) (author), Valerie Calvert (14961306) (author), Mariaelena Pierobon (14961309) (author), Jessica A. Sorrentino (14961312) (author), Andrew P. Beelen (14961315) (author), Natalie Bublitz (14961318) (author), Mareen Lüthen (14961321) (author), Kris C. Wood (14961324) (author), Emanuel F. Petricoin (14961327) (author), Christine Sers (12163648) (author), Autumn J. McRee (14961330) (author), Adrienne D. Cox (14953077) (author), Channing J. Der (14961333) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Cancer Biology Molecular and Cellular Biology Cell Cycle CDKs and CDK inhibitors Cell Signaling Guanine nucleotide binding proteins and effectors DNA Damage and Repair DNA damage Oncogenes & Tumor Suppressors Kras Oncogenes Rb and family
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
de réir: Juliana Navarro-Yepes (17079059)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
de réir: Sami Belhadj (15052341)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
de réir: Min Wei (16918572)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
de réir: Min Wei (16918572)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung
de réir: Koichi Tomoshige (15304682)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
de réir: Long Jiang (14956159)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
de réir: Long Jiang (14956159)
Foilsithe / Cruthaithe: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
de réir: Long Jiang (14956159)
Foilsithe / Cruthaithe: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
de réir: Xiaoqing Cheng (16918496)
Foilsithe / Cruthaithe: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
de réir: Lenka Stolarova (16547259)
Foilsithe / Cruthaithe: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
de réir: Lenka Stolarova (16547259)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3jtpsfmkvrn9osuo86j6p9ngd1